BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36632978)

  • 1. High local control and low ocular toxicity using ultra-low-dose "boom-boom" radiotherapy for indolent orbital lymphoma.
    Shelukar S; Fernandez C; Bas Z; Komarnicky L; Lally SE; Shields CL; Binder A; Porcu P; Alpdogan O; Martinez-Outschoorn U; Shi W
    Chin Clin Oncol; 2022 Dec; 11(6):44. PubMed ID: 36632978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy.
    Chelius M; Chau K; Yang J; Hajj C; Imber B; Yahalom J
    Hematol Oncol; 2021 Aug; 39(3):304-312. PubMed ID: 33733514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis.
    Eze C; Friedrich I; Hadi I; Schmidt-Hegemann NS; Hartoyo SN; Trauth R; Reitz D; Manapov F; Siefert A; Dreyling M; Belka C; Li M
    Eur J Haematol; 2022 Jul; 109(1):21-30. PubMed ID: 35276022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma.
    Rehn S; Elsayad K; Oertel M; Baehr A; Eter N; Haverkamp U; Lenz G; Eich HT
    Anticancer Res; 2020 Jul; 40(7):4041-4046. PubMed ID: 32620650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy of indolent orbital lymphomas : Two radiation concepts.
    König L; Stade R; Rieber J; Debus J; Herfarth K
    Strahlenther Onkol; 2016 Jun; 192(6):414-21. PubMed ID: 27160291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examining the utility of lower dose radiotherapy for localised primary ocular adnexal MALT lymphoma.
    Leeson S; Jayamohan J; Vu H; Sundaresan P
    J Med Radiat Sci; 2021 Sep; 68(3):269-273. PubMed ID: 33675287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.
    Fasola CE; Jones JC; Huang DD; Le QT; Hoppe RT; Donaldson SS
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):930-5. PubMed ID: 23726002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
    Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
    Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma in three consecutive cases.
    Yang X; Dalvin LA; Lim LS; Mashayekhi A; Shields JA; Shields CL
    Eur J Ophthalmol; 2021 Mar; 31(2):NP91-NP96. PubMed ID: 31760781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-low dose radiotherapy in the management of low-grade orbital lymphomas.
    de Castro B; Peixeiro RP; Mariz JM; Oliveira Â
    Rep Pract Oncol Radiother; 2022; 27(3):467-473. PubMed ID: 36186691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy.
    Woolf DK; Kuhan H; Shoffren O; Akinnawo EM; Sivagurunathan B; Boyce H; Plowman PN
    Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):153-9. PubMed ID: 25455843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Radiotherapy
    Baron J; Wright CM; Lee DY; Carpenter M; Manjunath SH; Briceño CA; Chong E; Maity A; Plastaras JP; Paydar I
    Front Oncol; 2021; 11():716002. PubMed ID: 34290991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.
    Pinnix CC; Dabaja BS; Milgrom SA; Smith GL; Abou Z; Nastoupil L; Romaguera J; Turturro F; Fowler N; Fayad L; Westin J; Neelapu S; Fanale MA; Rodriguez MA; Hagemeister F; Lee HJ; Oki Y; Wang M; Samaniego F; Chi L; Esmaeli B
    Head Neck; 2017 Jun; 39(6):1095-1100. PubMed ID: 28370694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular adnexal MALTomas: case series of patients treated with primary radiation.
    Russell W; Herskovic A; Gessert D; Cohen JA; Rubenstein JB; Gregory SA
    Clin Adv Hematol Oncol; 2013 Apr; 11(4):209-14. PubMed ID: 23604236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy: Results from a longitudinal study.
    Hoffmann C; Rating P; Bechrakis N; Eckstein A; Sokolenko E; Jabbarli L; Westekemper H; Mohr C; Schmeling C; Huettmann A; von Tresckow J; Göricke S; Deuschl C; Johansson P; Poettgen C; Gauler T; Guberina N; Moliavi S; Stuschke M; Guberina M
    Hematol Oncol; 2022 Dec; 40(5):922-929. PubMed ID: 35857866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes.
    Fung CY; Tarbell NJ; Lucarelli MJ; Goldberg SI; Linggood RM; Harris NL; Ferry JA
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1382-91. PubMed ID: 14630277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy for orbital lymphoma.
    Zhou P; Ng AK; Silver B; Li S; Hua L; Mauch PM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):866-71. PubMed ID: 15925453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-low-dose (boom-boom) radiotherapy for management of recurrent ocular post-transplant lymphoproliferative disorder.
    Astafurov KV; Bothun ED; Laack NN; Deisher AJ; Patel SV; Dalvin LA
    Am J Ophthalmol Case Rep; 2021 Sep; 23():101118. PubMed ID: 34041417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy for orbital lymphoma : outcome and late effects.
    Bischof M; Karagiozidis M; Krempien R; Treiber M; Neuhof D; Debus J; Zierhut D
    Strahlenther Onkol; 2007 Jan; 183(1):17-22. PubMed ID: 17225941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials.
    Reinartz G; Molavi Tabrizi C; Liersch R; Ullerich H; Hering D; Willborn K; Schultze J; Micke O; Ruebe C; Fischbach W; Bentz M; Daum S; Pott C; Tiemann M; Moeller P; Neubauer A; Wilhelm M; Lenz G; Berdel WE; Willich N; Eich HT
    Oncologist; 2020 May; 25(5):e816-e832. PubMed ID: 32219909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.